LANGHORNE, Pennsylvania, October 7, 2013 /PRNewswire/ --
Alliqua, Inc. provided an update on a series of independent news stories highlighting the Company's wound care portfolio and corporate developments. The links below provide direct access to each complete article.
Reports on Alliqua's corporate developments, including its transformation into a wound care products and technology company from a wound care contract manufacturer, its growth strategy, and recent strengthening of its management team, were carried in the Philadelphia Business Journal and Medical Device Daily. Separate reports of Alliqua's SilverSeal® hydrogel wound care dressing and its unique characteristics were featured in Manufacturing Chemist Pharma, WOUNDS and Qmed.com.
Links to the articles follow:
"Reinventing the Bandage with Hydrogels," on Qmed.com: http://www.qmed.com/mpmn/medtechpulse/reinventing-bandage-hydrogels
"Biopharm company gets new home, new focus," in Philadelphia Business Journal:
"Lidocaine hydrogel patches will be developed to treat localised acute pain," in the September issue of Manufacturing Chemist: http://www.manufacturingchemist.com/news/article_page/Lidocaine_hydrogel_patches_will_be_developed_to_treat_localised_acute_pain/91318
"Alliqua's SilverSeal Dressing Shown to Improve Surgical Wound Outcomes in Clinical Study," on the WOUNDS magazine website: http://www.woundsresearch.com/news/alliquas-silverseal-dressing-shown-improve-surgical-wound-outcomes-clinical-study
David Johnson, CEO of Alliqua, said, "As our company continues to meets its strategic growth objectives, we are pleased to receive recognition in the media for our achievements, both in terms of our portfolio of wound care products and our corporate developments, including Alliqua's strong management team."
About Alliqua, Inc.
Alliqua, Inc. (ALQA) ("Alliqua") is a biopharmaceutical company focused on the development, manufacturing, and distribution of proprietary transdermal wound care and drug delivery technologies. Alliqua's technology platform produces hydrogels, a 3-dimensional cross-linked network of water soluble polymers capable of numerous chemical configurations.
Alliqua currently markets its new line of 510(k) FDA-approved hydrogel products for wound care under the SilverSeal® brand, as well as the sorbion sachet S and sorbion sana wound care products. Alliqua's electron beam production process, located at its 16,000 square foot GMP manufacturing facility in Langhorne, PA, allows Alliqua to develop and custom manufacture a wide variety of hydrogels. Alliqua's hydrogels can be customized for various transdermal applications to address market opportunities in the treatment of wounds as well as the delivery of numerous drugs or other agents for pharmaceutical and cosmetic industries. Additionally, Alliqua's drug delivery platform, in combination with certain active pharmaceutical ingredients, can provide pharmaceutical companies with a transdermal technology to enhance patient compliance and potentially extend the patent life of valuable drug franchises.
Any statements contained in this press release regarding our ongoing research and development and the results attained by us to-date have not been evaluated by the Food and Drug Administration.
Legal Notice Regarding Forward-Looking Statements
This release contains forward-looking statements. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties outside of the our control that can make such statements untrue, including, but not limited to, inadequate capital, adverse economic conditions, intense competition, lack of meaningful research results, entry of new competitors and products, adverse federal, state and local government regulation, termination of contracts or agreements, technological obsolescence of our products, technical problems with our research and products, price increases for supplies and components, inability to carry out research, development and commercialization plans, loss or retirement of key executives and research scientists and other specific risks. We currently have no commercial products intended to diagnose, treat, prevent or cure any disease. The statements contained in this press release regarding our ongoing research and development and the results attained by us to-date have not been evaluated by the Food and Drug Administration. There can be no assurance that further research and development, and/or whether clinical trial results, if any, will validate and support the results of our preliminary research and studies. Further, there can be no assurance that the necessary regulatory approvals will be obtained or that we will be able to develop new products on the basis of our technologies. In addition, other factors that could cause actual results to differ materially are discussed in our Annual Report on Form 10-K/A filed with the SEC on May 16, 2013, and our most recent Form 10-Q filings with the SEC. Investors and security holders are urged to read these documents free of charge on the SEC's web site at http://www.sec.gov. We undertake no obligation to publicly update or revise our forward-looking statements as a result of new information, future events or otherwise.
Brian M. Posner
Chief Financial Officer
Dian Griesel Int'l.
Dian Griesel Int'l.
Susan Forman or Laura Radocaj
SOURCE Alliqua, Inc.